The United Kingdom and the United States have reached a major trade agreement that will guarantee no tariffs on UK drug shipments going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase spending on drugs through the public health system. This pledge ensures that tariffs on these key products will remain at zero for a timeframe of three years.
This agreement follows earlier statements to dramatically increase import taxes on patented pharmaceutical products, with figures mentioned as high as one hundred percent.
"This agreement with the United Kingdom bolsters the global environment for new treatments and establishes much-needed balance to American-British pharmaceutical trade," a release said.
Economic Importance
Drugs represent one of the UK's largest goods shipped to the America, which is by far the largest market for leading UK drugmakers.
Export figures show that in the one-year period leading up to September, the UK exported medicines worth £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This guarantee protects jobs, stimulates funding and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement includes several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
The deal comes amid a ongoing row between the sector and the British authorities over spending levels and regulatory access.
This friction were intensified by claims that US patients were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been paused or cancelled, while substantial investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
